Secondly, the majority of our patients were at CKD stages 4 and 5 at which the deranged metabolic axis of calcium-phosphate-PTH/FGF23 is well established as are the atherosclerotic changes driven by the progression of uremia. This evidence concerns the gene FGF23 and chronic kidney disease.